Clinical trials: Intravascular Ultrasound
Coronary Artery Disease
In Vitro and In Vivo Comparison Between Intravascular Ultrasound (IVUS) Systems
The purpose of this study is to investigate and compare the images obtained from coronary imaging catheters used in the treatment of coronary blockages both in a clinical setting with patients and in models.
- Trial name
- SAVOIR2 (NCT02154295)
- Testing
- Infraredx Test Catheter
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Infraredx
Atherosclerosis
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
- Trial name
- NCT00116831
- Testing
- Glipizide, rosiglitazone maleate
- Where
- 156 sites in United States, Argentina and 18 more
- Volunteers
- 672 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery…
- Trial name
- GLAGOV (NCT01813422)
- Testing
- Evolocumab
- Where
- 226 sites in United States, Argentina and 30 more
- Volunteers
- 970 people
- Sponsor
- Amgen
Chronic Venous Disorder, Venous Outflow Obstruction
Clinical Outcomes of IVUS-guided Stenting Using the Boston Scientific Vici® Venous Stent System in Treating Patients With Chronic Non-malignant Iliofemoral Vein Obstruction
The APAC VICI Study is a prospective, non-randomized, multicenter, single-arm study. The purpose of this study is to evaluate the clinical results of using the Boston Scientifc's Vici Venous Stent (Vici stent) to treat…
- Conditions
- Chronic Venous Disorder, Venous Outflow Obstruction, Systemic Vein Outflow of Iliofemoral Vein
- Trial name
- APAC VICI (NCT04856592)
- Testing
- Boston Scientific Vici® Venous Stent System, Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)
- Sponsor
- Boston Scientific Corporation
Coronary Disease, Coronary Arteriosclerosis
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary…
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
- Trial name
- ILLUSTRATE (NCT00134173)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 146 sites in United States, Belgium and 4 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Pulmonary Embolism, Deep Vein Thrombosis
Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System
The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF.
- Trial name
- NCT02394912
- Testing
- vena cava filter implantation (LUMIFI with Crux VCF System)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Volcano Corporation
Peripheral Artery Disease, PAD
Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
IVUS imaging will be utilized to assess performance of the Sponsor's Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA) in patients who have symptomatic peripheral artery disease (PAD) occurring in…
- Conditions
- Peripheral Artery Disease, PAD, Claudication, Peripheral Vascular Disease
- Trial name
- TRUTH (NCT01938391)
- Testing
- Stealth 360°® OAS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Acute Myocardial Infarction (AMI)
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized…
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery
- Trial name
- ZEPHYR (NCT07276282)
- Testing
- Ziltivekimab
- Where
- Switzerland
- Volunteers
- 332 people
- Sponsor
- ECRI bv
Peripheral Arterial Disease, Peripheral Vascular Disease
A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System
The Jetstream System is a commercially available rotating, aspirating, expandable catheter designed to remove atherosclerotic plaque and blood clots in the lower limbs.
- Trial name
- NCT00911417
- Testing
- Pathway Jetstream Atherectomy System
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pathway Medical Technologies Inc.
Coronary Heart Disease
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery…
- Trial name
- NCT00185042
- Testing
- Pactimibe, CS-505
- Where
- 46 sites in United States
- Volunteers
- 534 people
- Sponsor
- Daiichi Sankyo
Hypercholesterolemia, Acute Coronary Syndrome
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
Primary Objective: To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in…
- Trial name
- ODYSSEY J-IVUS (NCT02984982)
- Testing
- Alirocumab SAR236553, Atorvastatin, Rosuvastatin
- Where
- 39 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Sanofi